Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dendritic cell-activated cytokine-induced killer cells - Shenzhen Hornetcorn Biotechnology

Next Previous
Drug Profile

Dendritic cell-activated cytokine-induced killer cells - Shenzhen Hornetcorn Biotechnology

Alternative Names: Ag-D-CIK - Shenzhen Hornetcorn Biotechnology; Autologous dendritic cell cytokine-induced killer cell therapy - Shenzhen Hornetcorn; Autologous tumour lysate-pulsed DCIK - Shenzhen Hornetcorn; DC activated CIK - Shenzhen Hornetcorn Biotechnology; DC-CIK - Shenzhen Hornetcorn Biotechnology; DC-CIK Biotherapy - Shenzhen Hornetcorn Biotechnology; DCIK - Shenzhen Hornetcorn Biotechnology; Dendritic and cytokine-induced killer cells - Shenzhen Hornetcorn; Dendritic cell cytokine-induced killer cell therapy - Shenzhen Hornetcorn

Latest Information Update: 07 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen Hornetcorn Biotechnology
  • Developer Affiliated Tumor Hospital of Guangzhou Medical University; Shenzhen Hornetcorn Biotechnology
  • Class Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Cytokine-induced killer cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Solid tumours
  • Phase II Colorectal cancer; Gastric cancer; Liver cancer; Oesophageal cancer
  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 07 Sep 2022 Dendritic cell-activated cytokine-induced killer cells is still in phase-III trials for Solid tumours (Combination therapy, First-line therapy) in China (IV, infusion) (NCT04292769)
  • 25 Jul 2022 Phase-III development in Solid tumours (Combination therapy, First-line therapy) is ongoing in China (IV) (NCT04292769)
  • 21 Jan 2020 Phase-III clinical trials in Solid tumours (Combination therapy, First-line therapy) in China (IV) (NCT04292769)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top